| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED JULY 2018. Refer to TA538: Dinutuximab beta for treating neuroblastoma for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | dinutuximab beta (Qarziba®) | |
| Formulation | 4.5 mg/ml concentrate for solution for infusion | |
| Reference number | 2632 | |
| Indication | Treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease. Prior to the treatment of relapsed neuroblastoma, any actively progressing disease should be stabilised by other suitable measures. In patients with a history of relapsed/refractory disease and in patients who have not achieved a complete response after first line therapy, Dinutuximab beta Apeiron should be combined with interleukin 2 (IL 2) |
|
| Company | EUSA Pharma (Europe) Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Non-submission | |
| Status | Superseded | |
| Ratification by Welsh Government | 16/10/2017 | |
| Date of issue | 17/10/2017 | |
| NICE guidance | ||